New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Gilead Sciences, Inc.

GILD

Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.

Revenue
+6.83%
EPS
−20.2%
Free cash flow
+21.1%
Total debt
+5.17%

Quarter to September 2026, against a year earlier

168.64 2.11 +1.27%
Market cap
$207.8B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
1.95%
F-score
8/9
ROIC
−4.51%
Net debt / EBITDA
1.4×
Payout ratio
—

Gilead Sciences, Inc. 10-Q filed May 7, 2026

Fiscal Q1 2026 · Period ended Mar 31, 2026 · Filed · accepted 5:12 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 7, 2025: 19 added · 64 removed · 28 modified; 6 with only figures updated

  1. Modified

    The following discussion and analysis is intended to provide material information around events and uncertainties known to management that are relevant to an assessment of the financial condition and results of operations of Gilead and should therefore be read in conjunction with our audited Consolidated Financial Statements and the related notes thereto and other disclosures included as part of our Annual Report on Form 10-K for the year ended December 31, 20242025 and our unaudited Condensed Consolidated Financial Statements for the three and nine months ended September 30March 31, 20252026 and the related notes thereto and other disclosures (including the disclosures under Part II, Item 1A. Risk Factors) included in this Quarterly Report on Form 10-Q.